Eating Disorders · Texas behavioral health news
Entropy cleared to advance to second stage of binge eating study - The Australian
Eating Disorders (Google News) · June 15, 2026
In plain language
A clinical trial testing a new intravenous drug for binge eating disorder has been cleared to move into its next phase. The treatment uses psilocin, a compound found in certain mushrooms, alongside supportive therapy. Initial safety reviews of the first group of participants found no serious side effects or safety issues. Researchers are now expanding the study to include more patients to further test how well the treatment works to reduce binge eating behaviors.
AI-generated summary of the source article. Not medical advice.
Key takeaways
- Researchers are testing an intravenous form of psilocin to treat binge eating disorder.
- A safety board approved the trial to move to its second stage after positive early results.
- The first group of six participants experienced only mild to moderate side effects with no serious reactions.
- The treatment involves a 60-minute infusion combined with professional therapy sessions.
- Future study results will track changes in binge eating frequency and body mass index.
- Intravenous delivery allows doctors to control the depth and duration of the psychedelic experience more precisely.
Entropy cleared to advance to second stage of binge eating study The Australian
Need to talk to someone in Texas? Browse Texas-licensed telehealth therapists. In crisis, call or text 988.